SCHEMBL4006558

SCHEMBL4006558

CS(=O)(=O)c1ccccc1NS(=O)(=O)c1ccc2[nH]nc(NC(=O)c3ccccc3)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK7 P50613 8/20 0.50
▸ FGFR1 P11362 3/20 0.49
▸ FGFR3 P22607 3/20 0.49
▸ FGFR2 P21802 2/20 0.49
▸ AAK1 Q2M2I8 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.46
▸ JAK2 O60674 2/20 0.45
▸ CDC7 O00311 1/20 0.45
▸ PLK4 O00444 1/20 0.45
▸ CHEK1 O14757 1/20 0.45
▸ AURKA O14965 1/20 0.45
▸ DCLK1 O15075 1/20 0.45
▸ MAPK13 O15264 1/20 0.45
▸ PDPK1 O15530 1/20 0.45
▸ DAPK3 O43293 1/20 0.45
▸ ROCK2 O75116 1/20 0.45
▸ PRKD3 O94806 1/20 0.45
▸ MAP4K4 O95819 1/20 0.45
▸ PAK4 O96013 1/20 0.45
▸ CHEK2 O96017 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4009872 0.82 CSNK2A1 (0.55) JAK2MAP4K4CDK1MARK3FLT3
SCHEMBL1460525 0.82 LRRK2 (0.53) CDK7FGFR1FGFR3FGFR2AAK1
SCHEMBL4008083 0.82 CDK7 (0.48) CDK7FGFR1FGFR3FGFR2HDAC6
SCHEMBL4009012 0.81 KMT2A (0.46) POLBKMT2AMAPTTDP1LMNA
SCHEMBL4013522 0.81 POLB (0.52) TYK2FLT3CSNK2A1PAK1POLB
SCHEMBL4008442 0.80 MAP2K4 (0.48) AURKADCLK1PRKD3MAP4K4CHEK2
SCHEMBL4014544 0.80 MAPT (0.43) POLBKMT2AMAPTTDP1LMNA
SCHEMBL4009500 0.80 BRAF (0.45) CSNK2A1POLBKMT2AMAPTTDP1
SCHEMBL4017635 0.79 CCR2 (0.42) POLBKMT2AMAPTTDP1LMNA
SCHEMBL4008742 0.79 PTGES2 (0.45) POLBKMT2AMAPTTDP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 — — US disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 — — US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 CDK7 29/4885FGFR1 609/4885FGFR3 503/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 CDK7 33/4885FGFR1 725/4885FGFR3 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback